85. Idiopathic interstitial pneumonia Clinical trials / Disease details
Clinical trials : 598 / Drugs : 435 - (DrugBank : 116) / Drug target genes : 100 - Drug target pathways : 210
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05134727 (ClinicalTrials.gov) | November 18, 2021 | 15/11/2021 | Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants | A Double-blind, Randomized, Placebo-controlled Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of Oral AZD5055 Following Single and Multiple Ascending Doses | Idiopathic Pulmonary Fibrosis | Drug: AZD5055;Drug: Placebo | AstraZeneca | NULL | Recruiting | 18 Years | 45 Years | All | 104 | Phase 1 | United States |